Microbix Biosystems and Therapure Biopharma have signed a partnership agreement to manufacture and market water-based products to the pharmaceutical, biotechnology and other industries.

The partnership will expand the portfolio of Microbix products and increase capacity by leveraging Therapure's commercial scale manufacturing facility. Microbix will maintain the sales and marketing functions for the water-based program, while Therapure will manage manufacturing and product development. The products will remain under the Microbix brand. Financial details were not disclosed.

Microbix chief executive officer, William J. Gastle, said, "Therapure's capabilities will enable Microbix to expand our product line and market share of the growing water-based business in North America. Our partnership will enable us to provide a complete portfolio of water-based products which will drive sales higher while increasing customer satisfaction."

Thomas Wellner, president and chief executive officer of Therapure, said, "Therapure Biopharma is excited to partner with another Canadian-based biotechnology company. This opportunity enables Therapure to leverage our large water and buffer manufacturing capacity and our Health Canada licensed aseptic filling capabilities."

As a result of the agreement, Microbix will launch Microbix22, a new pre-mixed 22% alcohol and water-for-injection (WFI) for chromatography column storage. Additionally, the partnership will be able to manufacture custom buffers and media to recipes provided by customers.

News from our sister sites